Blueprint Medicines: FDA Approves Ayvakit to Treat Adults With Advanced Systemic Mastocytosis
June 16 2021 - 4:43PM
Dow Jones News
By Stephen Nakrosis
Blueprint Medicines Corp. on Wednesday said the Food and Drug
Administration has approved Ayvakit to treat adult patients with
advanced systemic mastocytosis.
The approval covers Ayvakit, or avapritinib, for the treatment
of advanced systemic mastocytosis, "including aggressive SM, SM
with an associated hematological neoplasm and mast cell leukemia"
the company said.
Advanced systemic mastocytosis can damage organs due to the
accumulation of mast cells, a type of white blood cell.
The company said it will host a live webcast beginning at 4:30
p.m. EDT to discuss the FDA approval.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 16, 2021 16:36 ET (20:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Apr 2023 to Apr 2024
